Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
Allogene Therapeutics (Nasdaq: ALLO) will announce its second quarter 2022 financial results on August 9, 2022, after market close. A conference call and live audio webcast will follow at 2 PM PT/5 PM ET. The webcast can be accessed on the company's website, with a replay available for 30 days. Allogene focuses on developing AlloCAR T™ products to provide accessible cell therapy for cancer patients. This initiative aims to enhance the reliability and scalability of treatment options.
- Anticipation of second quarter 2022 financial results could indicate progress in business operations.
- Development of off-the-shelf CAR T cell candidates positions the company for potential market growth.
- None.
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET
SOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2022 financial results on Tuesday, August 9, 2022, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 PM Pacific Time/5:00 PM Eastern Time.
Audio Webcast
The webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): (800) 715-9871
Live (International): (646) 307-1963
Conference ID: 7832993
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T products for cancer and the potential benefits of AlloCAR T. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Form 10-Q for the quarter ended March 31, 2022. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
FAQ
When will Allogene Therapeutics report their Q2 2022 financial results?
What is the time for the Allogene conference call?
How can I access the Allogene Therapeutics webcast?
What technology is Allogene Therapeutics developing?
What is the purpose of the Allogene Therapeutics pipeline?
